Arcturus director granted 15,000 stock options

Arcturus Therapeutics Holdings Inc. director Edward W. Holmes received a grant of stock options as part of his 2026 annual board compensation.

Rhea-AI Filing Summary

Arcturus Therapeutics Holdings Inc. director Edward W. Holmes received a grant of stock options as part of his 2026 annual board compensation. The award covers 15,000 options to buy common stock at an exercise price of $7.30 per share, expiring on June 5, 2036.

According to the footnote, the options vest monthly over one year from the grant date, meaning portions become exercisable each month during that period. This is a compensation-related grant, not an open-market purchase, and leaves Holmes with 15,000 derivative securities reported after the transaction.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider HOLMES EDWARD W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	15,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 15,000 contracts (Direct)

Footnotes (1)

1. F1. Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Key Figures

Options granted: 15,000 options Exercise price: $7.30 per share Expiration date: June 5, 2036 +2 more

5 metrics

Options granted 15,000 options 2026 annual grant to director Edward W. Holmes

Exercise price $7.30 per share Strike price for granted stock options

Expiration date June 5, 2036 Option term end date

Underlying shares 15,000 shares Common stock underlying the granted options

Total options after grant 15,000 options Reported derivative holdings following transaction

Key Terms

Stock option (right to buy), Grant, award, or other acquisition, Common Stock, Board of Directors, +1 more

5 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Board of Directors financial

"as a member of the Board of Directors of the Issuer"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

vest monthly over a one year period financial

"Shares underlying the option vest monthly over a one year period"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ARCT director Edward W. Holmes report on this Form 4?

Edward W. Holmes reported receiving a grant of 15,000 stock options to buy Arcturus Therapeutics common stock. The options were granted as part of his 2026 annual compensation for serving on the Board of Directors.

What is the exercise price of the new Arcturus (ARCT) stock options?

The granted stock options have an exercise price of $7.30 per share. This means Holmes can later purchase Arcturus common stock at $7.30, regardless of the market price at the time of exercise.

How many Arcturus (ARCT) options does Edward W. Holmes hold after this grant?

Following this grant, Holmes is reported as holding 15,000 stock options related to Arcturus common stock. These options were all acquired in this transaction and represent his reported derivative holdings after the grant.

When do the new Arcturus (ARCT) options granted to Holmes vest?

The options vest monthly over a one-year period starting from the grant date. Each month, a portion of the 15,000 options becomes exercisable, aligning with typical board compensation vesting schedules.

When do Edward W. Holmes’s Arcturus (ARCT) stock options expire?

The stock options granted to Holmes expire on June 5, 2036. After that date, any unexercised options will lapse, and he will no longer be able to buy Arcturus shares at the $7.30 exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOLMES EDWARD W

(Last) (First) (Middle)

C/O ARCTURUS THERAPEUTICS HOLDINGS INC.

10285 SCIENCE CENTER DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcturus Therapeutics Holdings Inc. [ ARCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)(1)	$7.3	06/05/2026		A		15,000		(1)	06/05/2036	Common Stock	15,000	$0.00	15,000	D

Explanation of Responses:

1. Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

	/s/ Ilan Katz, attorney-in-fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)